Siavash Atrchian, MD FRCPC

Clinical Associate Professor
Division of Radiation Oncology and Developmental Radiotherapeutics
UBC Department of Surgery

Active Staff, Radiation Oncologist
Department of Radiation Oncology
BC Cancer – Kelowna

Address:
BC Cancer – Kelowna
Sindi Ahluwalia Hawkins Centre for the Southern Interior
399 Royal Avenue
Kelowna BC V1Y 5L3

Phone: 250.979.6645
Fax: 250.712.3911

Special Interests

SABR (Stereotactic Ablative Radiotherapy)
Treatment of Lung, Breast and GI Malignancies
Role of Microbiome in Cancer Development
Cancer Care improvements and outcomes

Selected Publications and Abstracts

The Impact of ultracentral tumor location on outcomes in patients with pulmonary oligometastases: A secondary analysis of the single-arm phase 2 SABR-5 Trial

Baker S, Leclerc C, Atmanspacher-Wirth H, Zhao Y, Schellenberg D, Clark H, Mou B, Liu M, Hsu F, Berrang T, Atrchian S, Bergman A, Chng N, Matthews Q, Chang JS, Tyldesley S, Olsen R International Journal Radiation Oncology Biology Physics. 2025 Feb 7:S0360-3016(25)00096-3
doi: 10.1016/j.ijrobp.2025.01.031.

Optimizing the integration of family physicians into cancer survivorship care in the BC Interior: A mixed methods study of physicians’ opinions and experiences

Hayes BD, Young HG, Atrchian S, Bennett EV, Haynes EMK, Loader A, McCorquodale S, Stork MJ, Taki A, Voss C
Journal of Cancer Survival. 2025 Feb doi: 10.1007/s11764-025-01751-2

Translating printed patient education pamphlets to audio-visual digital resources

Guo I, Lin A, Campbell J, Atrchian S IHI 2025, Utrecht, Netherland, CARO 2024, Vancouver, BC

Inflammatory bowel disease and radiation therapy: Is it time to reconsider?

Yao S, Kulshrestha R, Atrchian S, Koulis T, Bahl G BC Cancer Summit, 2024, Vancouver, BC

Prognostication of non-small cell lung cancer with concurrent chemoradiation treatment using neutrophil-to-lymphocyte ratio
Xia YH, Huang H, Chang JS, Rao S, Shafiee A, Atrchian S CARO 2024, Vancouver, BC, BC Cancer Summit 2024, Vancouver, BC

A feasibility study of residential radon exposure and lung cancer in the Interior Health Authority Region of British Columbia, Canada
Huang C, Witham K, Lo J, Withers C, Nicol A, Forsman-Phillips L, Atrchian S IHI 2025, Utrecht, Netherland, CARO 2024, Vancouver, BC

Effects of palliative esophageal EBRT in patients with stent for esophageal cancer: Retrospective cohort study

Adams E, Lavoie-Gagnon H, Islam F, Humer M, Mou B, Koulis T, Kim D, Atrchian S CARO 2024, Vancouver, BC

Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET

Olson R, Abraham H, Leclerc C, Benny A, Baker S, Matthews Q, Chng N, Bergman A, Mou B, Dunne EM, Schellenberg D, Jiang W, Chan E, Atrchian S, Lefresne S, Carolan H, Valev B, Tyldesley S, Bang A, Berrang T, Clark H, Hsu F, Louie AV, Warner A, Palma DA, Howell D, Barry A, Dawson L, Grendarova P, Walker D, Sinha R, Tsai J, Bahig H, Thibault I, Koul R, Senthi S, Phillips I, Grose D, Kelly P, Armstrong J, McDermott R, Johnstone C, Vasan S, Aherne N, Harrow S, Liu M BMC Cancer. 2024 Feb 3;24(1):171. doi: 10.1186/s12885-024-11905-7

Predictors of quality of life decline in patients with oligometastases treated with stereotactic ablative radiotherapy: Analysis of the population-based SABR-5 Phase II Trial

Cruz-Lim EM, Mou B, Jiang W, Liu M, Bergman A, Schellenberg D, Alexander A, Berrang T, Bang A, Chng N, Matthews Q, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson R, Baker S. Clinical Oncology (R Coll Radiol). 2024 Mar ;36(3):141-147
doi: 10.1016/j.clon.2024.01.007

Upfront versus delayed systemic therapy in patients with oligometastatic cancer treated with SABR in the Phase 2 SABR-5 Trial

Baker S, Lechner L, Liu M, Chang JS, Cruz-Lim EM, Mou B, Jiang W, Bergman A, Schellenberg D, Alexander A, Berrang T, Bang A, Chng N, Matthews Q, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Arbour G, Yu I, Tyldesley S, Olson RA
International Journal Radiation Oncology Biology Physics. 2024 Apr 1;118(5):1497-1506 doi: 10.1016/j.ijrobp.2024.01.008

Prospective longitudinal assessment of quality of life after stereotactic ablative radiotherapy for oligometastases: Analysis of the population-based SABR-5 Phase II Trial

Cruz-Lim EM, Mou B, Baker S, Arbour G, Stefanyk K, Jiang W, Liu M, Bergman A, Schellenberg D, Alexander A, Berrang T, Bang A, Chng N, Mathews Q, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson R Clinical Oncology (R Coll Radiol). 2024 Mar;36(3):148-156 doi: 10.1016/j.clon.2023.11.041

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial

Eufemon Cereno R, Mou B, Baker S, Chng N, Arbour G, Bergman A, Liu M, Schellenberg D, Matthews Q, Huang V, Mestrovic A, Hyde D, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Jiang W, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson R Radiotherapy and Oncology. 2023 May ;182:109576 doi: 10.1016/j.radonc.2023.109576

Primary care provider-led cancer survivorship care in the first 5 years following initial cancer treatment: A scoping review of the barriers and solutions to implementation

Hayes BD, Young HG, Atrchian S, Vis-Dunbar M, Stork MJ, Pandher S, Samper S, McCorquodale S, Loader A, Voss C Journal of Cancer Survival. 2024 Apr;18(2):352-365. doi: 10.1007/s11764-022-01268-y

Validation of the prognostic utility of ESTRO/EORTC oligometastatic disease classification: A secondary analysis from the population-based Phase II SABR-5 Trial

Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson R International Journal Radiation Oncology Biology Physics. 2022 Dec 1;114(5):849-855 doi: 10.1016/j.ijrobp.2022.08.026

Treatment with Stereotactic Ablative Radiotherapy for up to 5 oligometastases in patients with cancer: Primary toxic effect results of the nonrandomized Phase 2 SABR-5 Clinical Trial

Olson R, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Baker S, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresene S, Tyldesley S JAMA Oncology. 2022 Nov 1;8(11):1644-1650. doi: 10.1001/jamaoncol.2022.4394

Predictors of early polymetastatic relapse after SABR for up to 5 oligometastases: A secondary analysis of the Phase II SABR-5 Trial

Progression-free survival and local control after SABR for up to 5 oligometastases: An analysis from the population-based Phase 2 SABR-5 Trial

Baker S, Jiang W, Mou B, Lund CR, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Chng N, Matthews Q, Arbour G, Benny A, Tyldesley S, Olson R International Journal Radiation Oncology Biology Physics. 2022 Nov 15;114(4):617-626
doi: 10.1016/j.ijrobp.2022.05.033

Clinical outcomes of pancoast tumors treated with trimodality therapy.

Lin TY, Atrchian S, Humer M, Siever J, Lin A Journal of Thoracic Disease. 2021 Jun;13(6):3529-3538. doi: 10.21037/jtd-21-380

Training and validation of Deep Learning-Based Auto-Segmentation models for lung Stereotactic Ablative Radiotherapy Using retrospective radiotherapy planning contours

Wong J, Huang V, Giambattista JA, Teke T, Kolbeck C, Giambattista J, Atrchian S Frontier of Oncology. 2021 Jun 7;11:626499. doi: 10.3389/fonc.2021.626499

Patient outcomes with dose escalation using modern radiotherapy techniques: A retrospective review of anal cancer treated at a large academic institution between 2010-2016

Murchison SC, DeVries KJ, Atrchian S Cureus. 2020 Oct 16;12(10):e10989. doi: 10.7759/cureus.10989

The microbiome and breast cancer: A review

Chen J, Douglass J, Prasath V, Neace M, Atrchian S, Manjili MH, Shokouhi S, Habibi M Breast Cancer Res Treat. 2019 Dec;178(3):493-496. doi: 10.1007/s10549-019-05407-5

Improvement of consistency in delineating breast lumpectomy cavity using surgical clips

Atrchian S, Sadeghi P, Cwajna W, Helyer L, Rheaume D, Nolan M, Sadeghi P, Robar J J Surg Res. 2018 Jan;221:30-34. doi: 10.1016/j.jss.2017.07.033

A British Columbia based population study on the treatment and long-term outcomes of Thymoma: A 25-Year Retrospective Review
Wu E, Sit D, Derocher H, Lin T, Lin A, Sauciuc D, Murchison S, Siever J, Atrchian S ASTRO 2022, San Antonio, USA, CARO 2022, Toronto, Canada

High-quality DNA extraction and gut microbial detection to evaluate pathologic response following neoadjuvant treatment for locally advanced rectal cancer
Sit D, Vojnits K, Yang H, Chen K, Zhao B, Rao S, Lee L, Davies J, Yang H, Pakpour S, Atrchian S CARO 2022, Toronto, Canada

Improving No-Show rates at BC Cancer – Kelowna using SMS reminders
Atrchian S, Darud M, Chow S, Ito C, Ponte K, Lali A International Forum on Quality and Safety in Healthcare 2022, Gothenburg, Sweden

Population-based phase II trial of SABR for up to 5 Oligometastases: Preliminary Results of the SABR-5 trial
Olson R, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F,
Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Huang V,
Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S ASTRO 2021, Chicago, USA

Axillary Lymph Node Coverage in Breast Cancer Patients Treated with Adjuvant Radiation Using High Tangent Fields Technique: A Single Institution’s Experience
Booth L, Kong T, Lali A, Lin A, Germain F, Lucas S, Rajapaksh R, Atrchian S Arch Breast Cancer. 2024; 11(1):75-81. DOI: 10.32768/abc.202411175-81

Wait times for adjuvant breast radiotherapy in the British Columbia Southern Interior
Mou B, McGregor S, Baliski C, Atrchian S, Lucas S, Lin A, Germain F, Mohamed I CARO 2017, Toronto, Canada

Supine vs. Prone positioning on reproducibility and acute toxicity for rectal cancer
Atrchian S, Hsu F, Badragan I, Yu R CARO 2013, Montreal, Canada

Intensity Modulated Radiation Therapy (IMRT) versus Chemo-IMRT in the treatment of stage III-IV Pharyngeal carcinoma: A retrospective study at the Nova Scotia Cancer Center
Atrchian S, Hollenhorst H, Wilke D, Rajaraman M CARO 2009, Quebec City, Canada